Glutamate carboxypeptidase II inhibition protects motor neurons from death in familial amyotrophic lateral sclerosis models
- 22 July 2003
- journal article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 100 (16) , 9554-9559
- https://doi.org/10.1073/pnas.1530168100
Abstract
Approximately 10% of cases of amyotrophic lateral sclerosis (ALS), a progressive and fatal degeneration that targets motor neurons (MNs), are inherited, and approximately 20% of these cases of familial ALS (FALS) are caused by mutations of copper/zinc superoxide dismutase type 1. Glutamate excitotoxicity has been implicated as a mechanism of MN death in both ALS and FALS. In this study, we tested whether a neuroprotective strategy involving potent and selective inhibitors of glutamate carboxypeptidase II (GCPII), which converts the abundant neuropeptide N-acetylaspartylglutamate to glutamate, could protect MNs in an in vitro and animal model of FALS. Data suggest that the GCPII inhibitors prevented MN cell death in both of these systems because of the resultant decrease in glutamate levels. GCPII inhibition may represent a new therapeutic target for the treatment of ALS.Keywords
This publication has 41 references indexed in Scilit:
- Synthesis and Biological Evaluation of Thiol-Based Inhibitors of Glutamate Carboxypeptidase II: Discovery of an Orally Active GCP II InhibitorJournal of Medicinal Chemistry, 2003
- Deletion of the glutamate carboxypeptidase II gene in mice reveals a second enzyme activity that hydrolyzes N‐acetylaspartylglutamateJournal of Neurochemistry, 2002
- Modulation of behavioral sensitization to cocaine by NAALADase inhibitionSynapse, 2000
- N‐AcetylaspartylglutamateJournal of Neurochemistry, 2000
- Functional Role of Caspase-1 and Caspase-3 in an ALS Transgenic Mouse ModelScience, 2000
- Benefit of vitamin E, riluzole, and gababapentin in a transgenic model of familial amyotrophic lateral sclerosisAnnals of Neurology, 1996
- Design, Synthesis, and Biological Activity of a Potent Inhibitor of the Neuropeptidase N-Acetylated α-Linked Acidic DipeptidaseJournal of Medicinal Chemistry, 1996
- A Controlled Trial of Riluzole in Amyotrophic Lateral SclerosisNew England Journal of Medicine, 1994
- Abnormal excitatory amino acid metabolism in amyotrophic lateral sclerosisAnnals of Neurology, 1990
- N‐Acetyl‐Aspartyl‐Glutamate: Regional Levels in Rat Brain and the Effects of Brain Lesions as Determined by a New HPLC MethodJournal of Neurochemistry, 1984